Liver Transplantation
Conditions
Brief summary
Normothermic machine perfusion (NMP) preservation is a promising method to decrease the complication of marginal donor livers compared to cold storage (CS). The aim of this project is to assess safety and feasibility of NMP in human liver transplantation. This will be a single center prospective cohort pilot study. Thirty-two livers with acceptable quality for transplantation will be preserved with NMP in 2-18 hours and transplanted. The follow-up period will be 6 months post-transplantation. The outcome will be compared to 100 historical patients transplanted in our program in the past 5 years (liver preserved using CS) with matched characteristics on age, Model for End-Stage Liver Disease (MELD) score, preservation time, etc.
Detailed description
The shortage of donor organs leads to the use of marginal donors including donors after cardiac death. Normothermic machine perfusion (NMP) preservation is a promising method to decrease their high risk of complication compared to the standard cold storage (CS). The aim of this project is to assess safety and feasibility of NMP in human liver transplantation. This will be a single center prospective cohort pilot study. Thirty-two livers that have acceptable quality for transplantation will be preserved with NMP in 2-18 hours after cross clamp and cold flush. The liver grafts at NMP will be at physiological temperature and have oxygen and nutrient supply with continuous perfusion. The transplantation and post-transplant care will follow the standard of care. The follow-up period is 12 months after transplantation. The primary end point will be the rate of post-transplant Early Allograft Dysfunction (EAD), while the secondary end points will be: primary non function (PNF) rate, 1 and 6 months patient and graft survival, peak liver function tests in the first 7 days after transplantation, intraoperative hepatic arterial and portal flow measurement, rate and magnitude of post-reperfusion syndrome, surgical outcomes (operative time, transfusion requirement etc.), rate of post-transplant kidney failure, assessment of histological ischemia reperfusion (liver and bile duct), rate of vascular complications, rate of biliary complications, hospital and ICU length of stay, rejection rate, infection rate, the ability to predict function based on on-pump viability markers, and the incidence of adverse effect (AE). The outcome will be compared to a control group of 100 historical patients (matched with a 1:4 ratio) transplanted in our program in the past 10 years (liver preserved using CS). Control subjects will be matched using donor and recipient age, Model for End-Stage Liver Disease (MELD) score, cold ischemia time, donor risk index and presence of steatosis.
Interventions
DEVICENormothermic Liver perfusion Device
The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
Sponsors
Cristiano Quintini
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients undergoing primary liver transplantation * Age 18-75 years at the time of transplantation * Willingness and ability to comply with the study procedures * Signed Informed Consent Form * For patients with hepatocellular carcinoma as indication for Orthoptic Liver Transplantation (OLT), tumor must be within Milan Criteria or down-staged to Milan Criteria.
Exclusion criteria
Recipient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the rate of Early Allograft Dysfunction post-transplantation in Normothermically Machine Perfused (NMP) livers | 7 days post-transplantation | The presence of at least one of the following at post-transplant 7 days: serum bilirubin \>= 10 mg/dL, international normalized ratio (INF) \>= 1.6; and/or aspartate aminotransferase (AST) \> 2000 U/L at any time in the first 7 post-transplant days (POD) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| graft survival | 6 months post-transplantation | The allograft will be considered lost if a patient has a liver re-transplant or in the event of patient death. |
| peak liver function tests in the first 7 days post-transplantation | in the first 7 days post-transplantation | — |
| intraoperative flow measurement | intraoperative | Flows will be measured with a transit time flowmeter (VeriQ system, MediStim A/S, Oslo, Norway) after graft reperfusion. The following parameters will be recorded as per our standard practice during liver transplantation: portal venous flow, hepatic artery flow, and hepatic artery flow after temporary portal vein occlusion. |
| post reperfusion syndrome (composite) | in the first 7 days post-transplantation | rate and magnitude |
| surgical outcomes (composite) | intraoperative | operative time, transfusion requirement |
| rate of post-transplant kidney failure | in the 1, 3, 6 ,9 months post-transplantation | — |
| histology of liver parenchyma | On the day of transplantation | — |
| primary non-function rate | in the first 10 days post-transplantation | — |
| biliary complications rate | 6 months post-transplantation | — |
| hospital and ICU length of stay (composite) | 6 months post-transplantation | — |
| rejection rate | 6 months post-transplantation | — |
| opportunistic viral infection rate | 6 months post-transplantation | — |
| patient survival | 6 months post-transplantation | — |
| histology of bile duct | On the day of transplantation | — |
| vascular complications rate | in the first day post-transplantation | — |
Countries
United States
Outcome results
None listed